Summary

Adults with attention deficit hyperactivity disorder may benefit from an oral regimen of dasotraline, which inhibits reuptake of dopamine and norepinephrine. Deficiencies of both compounds have been associated with attention deficit hyperactivity disorder symptoms. The 4-week, randomized, double-blind, placebo-controlled trial provided proof-of-concept for dasotraline use, and should prompt further clinical trials and dose optimization.